S
1.75
0.04 (2.05%)
| Previous Close | 1.71 |
| Open | 1.74 |
| Volume | 1,270,227 |
| Avg. Volume (3M) | 3,386,991 |
| Market Cap | 393,593,504 |
| Price / Book | 1.48 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -1.16 |
| Total Debt/Equity (MRQ) | 40.68% |
| Current Ratio (MRQ) | 3.54 |
| Operating Cash Flow (TTM) | -223.15 M |
| Levered Free Cash Flow (TTM) | -168.60 M |
| Return on Assets (TTM) | -31.82% |
| Return on Equity (TTM) | -99.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Sana Biotechnology, Inc. | Bullish | Bearish |
AIStockmoo Score
1.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 1.25 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.59% |
| % Held by Institutions | 93.73% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (HC Wainwright & Co., 530.37%) | Buy |
| Median | 7.00 (301.15%) | |
| Low | 5.00 (Citizens Capital Markets, 186.53%) | Buy |
| Average | 7.67 (339.54%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Apr 2025 | 11.00 (530.37%) | Buy | 1.77 |
| 18 Mar 2025 | 11.00 (530.37%) | Buy | 2.28 | |
| Citizens Capital Markets | 18 Mar 2025 | 5.00 (186.53%) | Buy | 2.28 |
| Jefferies | 14 Mar 2025 | 7.00 (301.15%) | Buy | 2.93 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 May 2025 | Announcement | Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference |
| 08 May 2025 | Announcement | Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates |
| 17 Mar 2025 | Announcement | Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates |
| 24 Feb 2025 | Announcement | Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |